MedPath

classification of gastric and gastro-esophageal cancers based on expression of immunohistochemical markers

Not Applicable
Conditions
Health Condition 1: C16- Malignant neoplasm of stomach
Registration Number
CTRI/2021/04/032945
Lead Sponsor
IPSIT ILAHI
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1)Age > 18years

2)Biopsy proven primary adenocarcinoma of

the gastric and gastro-esophageal

junction

3)Willing to undergo staging

investigations

4)Consenting to participate in the study

Exclusion Criteria

1.Insufficient tissue sample for

immuno-histochemical study

2.Prior anti-cancer treatment

3.History of prior malignancy

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The prevalence of various immunohistochemical markers (EBV, MSI, TP53) in gastric and GE junction tumors in North Indian patientsTimepoint: At the time of diagnosis
Secondary Outcome Measures
NameTimeMethod
Correlation of immuno-histochemical based classification of gastric and GE junction tumors with disease stageTimepoint: At the time of diagnosis
© Copyright 2025. All Rights Reserved by MedPath